L&T Finance Limited (LTF.NS)
INR 140.51
(-0.36%)
INR 140.51
(-0.36%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 73.55 Billion | 65.21 Billion | 55.9 Billion | 34.9 Billion | 69.6 Billion |
| Cost of Revenue | 1.63 Billion | - | - | - | 1.63 Billion |
| Gross Profit | 71.91 Billion | 65.21 Billion | 55.9 Billion | 34.9 Billion | 67.96 Billion |
| Operating Expenses | 19.55 Billion | 28.33 Billion | 22.63 Billion | -5.23 Billion | 11.2 Billion |
| Selling, General and Administrative Expenses | 19.55 Billion | 6.62 Billion | 4.03 Billion | 2.35 Billion | 11.2 Billion |
| Research and Development Expenses | - | - | - | - | - |
| Other Expenses | - | - | - | - | - |
| Cost and Expenses | 19.55 Billion | 28.33 Billion | 22.63 Billion | -5.23 Billion | 11.2 Billion |
| Operating Income | - | 17.95 Billion | 14.43 Billion | 14.94 Billion | 58.4 Billion |
| Interest Expense | 53.77 Billion | 57.97 Billion | 57.53 Billion | 72.12 Billion | 75.13 Billion |
| Income Tax Expense | 7.11 Billion | 1.72 Billion | 3.73 Billion | 5.23 Billion | 9.79 Billion |
| Earnings before Tax | 30.29 Billion | -5.56 Billion | 12.22 Billion | 12.61 Billion | 26.8 Billion |
| Net Income | 23.2 Billion | 16.23 Billion | 10.7 Billion | 9.7 Billion | 17 Billion |
| Earnings Per Share Basic | 9.34 | 6.56 | 4.33 | 4.49 | 8.00 |
| Earnings Per Share Diluted | 9.30 | 6.54 | 4.32 | 4.47 | 7.97 |
| Weighted Average Shares Outstanding | 2.48 Billion | 2.47 Billion | 2.47 Billion | 2.16 Billion | 2.13 Billion |
| Weighted Average Shares Outstanding (Diluted) | 2.49 Billion | 2.48 Billion | 2.47 Billion | 2.17 Billion | 2.13 Billion |
| Gross Margin | 0.98 | 1.00 | 1.00 | 1.00 | 0.98 |
| EBIT Margin | 1.02 | 0.29 | 0.28 | 0.45 | 1.52 |
| Profit Margin | 0.32 | 0.25 | 0.19 | 0.28 | 0.24 |
| EBITDA | 74.91 Billion | - | - | - | 105.68 Billion |
| Earnings Before Tax Margin | - | 0.28 | 0.26 | 0.43 | 0.84 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 24.47 Billion | 22.78 Billion | 19.25 Billion | 78.59 Billion | 20.5 Billion | 16.5 Billion |
| Cost of Revenue | 15.09 Billion | 13.79 Billion | - | - | - | - |
| Gross Profit | 9.38 Billion | 8.98 Billion | 19.25 Billion | 78.59 Billion | 20.5 Billion | 16.5 Billion |
| Operating Expenses | 9.57 Billion | 9.65 Billion | 10.66 Billion | 35.07 Billion | 8.6 Billion | 8.59 Billion |
| Selling, General and Administrative Expenses | - | 5.19 Billion | - | - | - | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 9.57 Billion | 9.65 Billion | - | - | - | - |
| Cost and Expenses | 24.34 Billion | 9.65 Billion | 10.66 Billion | 35.07 Billion | 8.6 Billion | 8.59 Billion |
| Operating Income | 14.9 Billion | 9.22 Billion | 6.94 Billion | 30.32 Billion | 8.24 Billion | 7.98 Billion |
| Interest Expense | 14.76 Billion | 13.51 Billion | 13.35 Billion | 53.77 Billion | 13.53 Billion | 13.24 Billion |
| Income Tax Expense | 2.42 Billion | 2.37 Billion | 1.41 Billion | 7.11 Billion | 1.84 Billion | 2.03 Billion |
| Earnings before Tax | 9.39 Billion | 9.22 Billion | 6.94 Billion | 30.29 Billion | 8.24 Billion | 7.97 Billion |
| Net Income | 6.95 Billion | 6.85 Billion | 5.53 Billion | 23.2 Billion | 6.4 Billion | 5.95 Billion |
| Earnings Per Share Basic | 2.79 | 2.75 | 2.23 | - | 2.57 | 2.40 |
| Earnings Per Share Diluted | 2.78 | 2.74 | 2.22 | - | 2.57 | 2.39 |
| Weighted Average Shares Outstanding | 2.49 Billion | 2.49 Billion | 2.48 Billion | 2.48 Billion | 2.49 Billion | 2.47 Billion |
| Weighted Average Shares Outstanding (Diluted) | 2.5 Billion | 2.5 Billion | 2.49 Billion | 2.49 Billion | 2.49 Billion | 2.49 Billion |
| Gross Margin | 0.38 | 0.39 | 1.00 | 1.00 | 1.00 | 1.00 |
| EBIT Margin | 0.62 | 0.42 | 0.36 | - | 0.42 | 0.50 |
| Profit Margin | 0.28 | 0.30 | 0.29 | 0.30 | 0.31 | 0.36 |
| EBITDA | 15.23 Billion | 9.5 Billion | 6.94 Billion | - | 8.54 Billion | 8.26 Billion |
| Earnings Before Tax Margin | 0.61 | 0.40 | 0.36 | 0.39 | 0.40 | 0.48 |
GLAND
5076
CONCORDBIO
VLSFINANCE
HBMN
OCGPF